In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Bio-Rad Laboratories, Inc. stands amongst them. Bio-Rad Laboratories, Inc. (NYSE:BIO), a global ...

Timegate Instruments Ltd, developer and manufacturer of time-gated Raman spectrometers and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical ...

Bio-Rad develops products and solutions for the life science research and clinical diagnostic markets and has niche market leadership in diagnostic quality controls, antigens, and digital polymerase ...

Edinburgh, UK -- To mark the recent launch of Edinburgh Instruments' new RM5 Raman Microscope, the company has announced its partnership with Bio-Rad and its KnowItAll Raman Spectral Identification ...

Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...

Bio-Rad’s business relies on the razor/razor blade model typically seen in the diagnostic market, and consumable reagents account for approximately 65% of total sales, with these reagents generally ...

LONDON--(BUSINESS WIRE)--The electroporation instruments market is poised to grow by USD 72.67 million during 2020-2024, during the forecast period. Request free sample pages Read the 120-page report ...

Bio-Rad Laboratories, Inc. (BIO) has experienced a rise in revenue growth in recent years thanks to strong sales of its Western Blotting, Digital PCR, and Process Media life science products. Several ...

DUBLIN, May 14, 2020 /PRNewswire/ -- The "High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These ...